1. Home
  2. PHAR vs TBPH Comparison

PHAR vs TBPH Comparison

Compare PHAR & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$16.39

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$17.59

Market Cap

993.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHAR
TBPH
Founded
1988
2013
Country
Netherlands
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
993.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PHAR
TBPH
Price
$16.39
$17.59
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$30.00
$27.80
AVG Volume (30 Days)
21.0K
535.4K
Earning Date
11-06-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.00
0.58
Revenue
$362,274,000.00
$80,327,000.00
Revenue This Year
$24.80
$70.78
Revenue Next Year
$6.84
N/A
P/E Ratio
$3,084.39
$31.31
Revenue Growth
26.78
27.12
52 Week Low
$7.50
$7.90
52 Week High
$18.12
$20.33

Technical Indicators

Market Signals
Indicator
PHAR
TBPH
Relative Strength Index (RSI) 49.79 49.22
Support Level $15.76 $17.25
Resistance Level $18.12 $18.36
Average True Range (ATR) 0.83 0.71
MACD -0.12 -0.28
Stochastic Oscillator 28.81 10.59

Price Performance

Historical Comparison
PHAR
TBPH

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: